VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Trial ID or NCT#

NCT01289210

Status

not recruiting iconNOT RECRUITING

Purpose

This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Official Title

A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * low grade B cell lymphoma* 1 or more sites of disease appropriate for intratumoral injection* measurable disease other than the injection site* Performance Status of 1 or better* Adequate bone marrow, renal and hepatic function* No active autoimmune disease or systemic immunosuppressive drugs* Life expectancy \> 4 months
Exclusion Criteria:
  1. * Known HIV* Known brain metastases* Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)* Anticoagulation therapy other than 325mg QD ASA* Significant cardiovascular disease* Pregnant or nursing
View All Criteria
Show Less

Investigator(s)

Manali Patel
Manali Patel
Medical oncologist
Associate Professor of Medicine (Oncology)
Ash A. Alizadeh, MD/PhD
Ash A. Alizadeh, MD/PhD
Medical oncologist, Lymphoma specialist, Cancer geneticist
Moghadam Family Professor

Contact us to find out if this trial is right for you.

Contact

Lori Richards
6507258589

View on ClinicalTrials.gov